RECRUITING

Acceptance and Commitment Therapy (ACT-HBC) for the Improvement of Cancer Distress in Patients With Hepatobiliary Cancers

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This clinical trial studies whether Acceptance and Commitment Therapy for patients with hepatobiliary cancers (ACT-HBC) can be used to help improve cancer distress. Patients with hepatobiliary cancer (HBC) often experience high levels of distress and reductions in quality of life. ACT-HBC is a behavioral intervention tailored to patients with HBC. It helps patients cope with difficult thoughts and emotions while staying connected to what matters most in life, which may be an effective way to improve cancer distress.

Official Title

Development of Acceptance and Commitment Therapy for Cancer Distress Among Rural and Urban Patients With Hepatobiliary Cancers (ACT-HBC)

Quick Facts

Study Start:2025-05-28
Study Completion:2027-05-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT07124546

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * HBC diagnosis
  2. * Age \>= 18 years
  3. * Able to provide written informed consent
  4. * Verbally endorse cancer distress
  5. * Access to the internet
  6. * Read and write in English
  7. * Reside in the states of Iowa, Minnesota, or Wisconsin
  1. * Other psychological therapy that started =\< 2 months prior to prospective enrollment
  2. * Inability to actively participate in and learn from group therapy (e.g., active/uncontrolled psychotic symptoms, neurological condition, personality pathology) as determined by clinical judgement in Behavioral Medicine Program (BMP) consultation. Individual therapy or alternative group therapy will be offered to patients ineligible per this criterion
  3. * HBC remission

Contacts and Locations

Study Contact

Sofia Hammel
CONTACT
507-255-0760
Hammel.Sofia@mayo.edu
Deanna Hofschulte
CONTACT
507-255-2972
Hofschulte.Deanna@mayo.edu

Principal Investigator

Carrie A Bronars, PhD, LP
PRINCIPAL_INVESTIGATOR
Mayo Clinic in Rochester

Study Locations (Sites)

Mayo Clinic in Rochester
Rochester, Minnesota, 55905
United States

Collaborators and Investigators

Sponsor: Mayo Clinic

  • Carrie A Bronars, PhD, LP, PRINCIPAL_INVESTIGATOR, Mayo Clinic in Rochester

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-05-28
Study Completion Date2027-05-30

Study Record Updates

Study Start Date2025-05-28
Study Completion Date2027-05-30

Terms related to this study

Additional Relevant MeSH Terms

  • Malignant Hepatobiliary Neoplasm